Comprehensive Assessment of the Safety of a New Antituberculosis Drug from the Diarylquinolines Group
https://doi.org/10.33647/2074-5982-17-3-105-110
Abstract
The safety of the new anti-tuberculosis drug Tiozonide was studied by bioinformatics and preclinical methods using laboratory animals and with the participation of healthy volunteers. The absence of toxic effects on the main life support systems of mammals predicted by QSAR models was confi rmed by the results of acute, subchronic and chronic toxicity tests in various laboratory animals. Monitoring of the vital indicators of volunteers and a comparative analysis of the generalized results of these indicators before (screening), during and after the study showed the absence of reliable and clinically signifi cant changes that threaten the life and health of people.
About the Authors
A. Yu. Savchenko
Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Аlla Yu. Savchenko
143442, Russian Federation, Moscow Region, Krasnogorsk District, Svetlye Gory Village, 1
G. V. Ramenskaya
I.M. Sechenov Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Galina V. Ramenskaya, Dr. of Sci. (Pharm.), Prof.
119991, Russian Federation, Moscow, Trubetskaya Str., 8, building 2
V. G. Kukes
Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Vladimir G. Kukes, Acad. of the Russian Academy of Sciences, Dr. Sci. (Med.), Prof.
143442, Russian Federation, Moscow Region, Krasnogorsk District, Svetlye Gory Village, 1
M. S. Burenkov
Pharm-Sintez
Russian Federation
Russian Federation
Mikhail S. Burenkov, Cand. Sci. (Biol.)
111024, Russian Federation, Moscow, 2nd Kabelnaya Str., 2, building 46
B. V. Shilov
Russian National Research Medical University Named after N.I. Pirogov of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Boris V. Shilov, Cand. Sci. (Med.), Assoc. Prof.
117997, Russian Federation, Moscow, Ostrovityanova Str., 1
References
1. Bocharova I.V., Burenkov M.S., Lepekha L.N., Smirnova T.G., Chernousova L.N., Demihova O.V. Doklinicheskiye issledovaniya spetsifi cheskoy aktivnosti novogo protivotuberkuleznogo preparata tiozonid [Preclinical studies of the specific activity of the new anti-TB drug thiosonide]. Tuberkulioz i bolezni legkih [Tuberculosis and lung disease]. 2014;(6):46–50. (In Russian)]. DOI: 10.21292/2075-1230-2014-0-6-46-50.
2. Men’shikova L.A. Farmakokineticheskoye issledovaniye original’nogo lekarstvennogo sredstva tiozonida [Pharmacokinetic study of the original drug thiosonide]: Autoref. of diss. … cand. pharm. sci. Moscow, 2016. (In Russian).
3. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. Chast’ pervaya [Guidelines for preclinical studies of drugs. Part one]. Moscow: Grif i K Publ., 2012:944. (In Russian).
4. Filinyuk O.V., Fel’ker I.G., Yanova G.V., Bujnova L.N., Kolokolova O.V. Faktory riska neeffektivnoy khimioterapii bol’nykh tuberkulezom s mnozhestvennoy lekarstvennoy ustoychivost’yu [Risk factors for ineffective chemotherapy for multidrug-resistant tuberculosis patients]. Tuberkulioz i bolezni legkih [Tuberculosis and lung disease]. 2014;1:20–26. (In Russian).
5. Shchegertsov D.Yu., Filinyuk O.V., Bujnova L.N., Zemlyanaya N.A., Kabanec N.N., Alliluev A.S. Nezhelatel’nye pobochnye reaktsii pri lechenii bol’nykh tuberkulezom s mnozhestvennoy lekarstvennoy ustoychivost’yu vozbuditelya [Undesirable adverse reactions in the treatment of patients with multidrug-resistant tuberculosis of the pathogen]. Tuberkulioz i bolezni legkih [Tuberculosis and lung disease]. 2018;96(3):35–43. (In Russian).
6. Harris M., Taylor G. Medical statistics made easy. London: Taylor and Francis, 2006.
7. Lagunin A., Rudik A., Filimonov D., Druzhilovsky D., Poroikov V. ROSC-Pred: web-service for rodent organ-specific carcinogenicity prediction. 2017;34(4):710–712. DOI: 10.1093/bioinformatics/btx678.
8. Lagunin A., Zakharov A., Filimonov D., Poroikov V. QSAR modelling of rat acute toxicity on the basis of PASS prediction. Mol. Informatics. 2011;30(2–3):241–250.
9. Lagunin A.A., Dubovskaja V.I., Rudik A.V., Pogodin P.V., Druzhilovskiy D.S., Gloriozova T.A., Filimonov D.A., Sastry G.N., Poroikov V.V. CLCPred: a freely available web-service for in silico prediction of human cell line cytotoxicity for drug-like compounds. PLOS One. 2018;13(1):e0191838. DOI: 10.1371/journal.pone.0191838.
10. Lagunin A.A., Dubovskaja V.I., Rudik A.V., Pogodin P.V., Druzhilovskiy D.S., Gloriozova T.A., Filimonov D.A., Sastry G.N., Poroikov V.V. CLCPred: a freely available web-service for in silico prediction of human cell line cytotoxicity for drug-like compounds. PLOS One. 2018;13(1):e0191838. DOI: 10.1371/journal.pone.0191838.
11. Zakharov A.V., Lagunin A.A., Filimonov D.A., Poroikov V.V. Quantitative prediction of antitarget interaction profi les for chemical compounds. Chemical Research in Toxicology. 2012;25(11):2378–2385. DOI: 10.1021/tx300247r.
12. http://www.way2drug.com/gusar/acutoxpredict.html
13. http://way2drug.com/Cell-line/index.php
14. http://www.oecd.org/chemicalsafety/
15. http://www.way2drug.com/gusar/antitargets.html
16. http://www.way2drug.com/ROSC/
Review
For citations:
Savchenko A.Yu., Ramenskaya G.V., Kukes V.G., Burenkov M.S., Shilov B.V. Comprehensive Assessment of the Safety of a New Antituberculosis Drug from the Diarylquinolines Group. Journal Biomed. 2021;17(3):105-110. (In Russ.) https://doi.org/10.33647/2074-5982-17-3-105-110
Views:
506
Email this article 
